NAD+ and Ketamine: Promising Treatments for Depression?

What Is NAD+?

NAD+ (nicotinamide adenine dinucleotide) and ketamine are two substances that have gained interest in recent years for their potential as treatments for depression. While they work in different ways, both have shown promise in studies as possible treatments for depression that may offer faster and more sustained relief than traditional antidepressants.

NAD+ is a coenzyme that is involved in many cellular processes, including energy metabolism and DNA repair. It has been shown to have a number of potential health benefits, including as a treatment for addiction, chronic fatigue syndrome, and neurodegenerative diseases.

‍

Sources:

• Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., ... & Sharma, V. (2018). Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar disorders, 20(2), 97-170.
• Martín-Hernández, D., Tendilla-Beltrán, H., Madrigal-Burgaleta, R., González-Bernal, J. J., Rodríguez-Rivas, M. J., Moreno-Carretero, M. J., ... & Méndez-Gallardo, V. (2021). NAD+ and Depression: A Systematic Review of Human and Animal Studies. Journal of Clinical Medicine, 10(4), 705.
• Zarate Jr, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., ... & Manji, H. K. (2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of general psychiatry, 63(8), 856-864.
• Wilkinson, S. T., Sanacora, G., & Krystal, J. H. (2017). A new era of rapid-acting antidepressants: novel ketamine analogs. The Journal of clinical psychiatry, 78(6), e605-e613.
• Miller, O. H., Yang, L., Wang, C. C., Hargroder, E. A., Zhang, Y., Delpire, E., ... & Cahill, M. E. (2020). GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine. eLife, 9, e55544.